This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of bone and articular cartilage of other and unspecified sites, excluding all cancers (controls excluding all cancers)
C3_BONE_CARTILAGE_NAS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
418 |
4. Check minimum number of eventsNone |
418 |
5. Include endpointsNone |
418 |
6. Filter based on genotype QC (FinnGen only) |
418 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of bone and articular cartilage of other and unspecified sites, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of bone and articular cartilage, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 418 | 194 | 224 |
| Unadjusted period prevalence (%) | 0.08 | 0.07 | 0.10 |
| Median age at first event (years) | 55.85 | 55.82 | 55.87 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 155
- Matched controls
- 1549
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB02
ATC
dexamethasone; systemic
140.4
54.1
55
6
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
98.2
45.1
48
7
130
Kela drug reimbursment
Malignant tumour
+∞
42.7
39
*
JN4BD
NOMESCO Finland
Extensive body CT
25.0
39.5
57
35
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
106.7
37.9
40
5
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
+∞
33.6
31
*
L03AA02
ATC
filgrastim; parenteral
402.9
33.2
32
*
XX3DW
NOMESCO Finland
Time consuming IT work
26.7
33.0
46
24
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
31.3
29
*
C90.0
ICD-10 Finland
Multiple myeloma
+∞
30.2
28
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
7.4
28.9
95
274
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
28.0
26
*
A04AA02
ATC
granisetron; systemic, transdermal
309.9
26.6
26
*
N02AA05
ATC
oxycodone; systemic
9.6
26.1
59
93
XW000
NOMESCO Finland
Bone marrow biopsy
25.6
25.8
36
18
WF002
NOMESCO Finland
Radical radiotherapy
+∞
25.7
24
*
A03FA01
ATC
metoclopramide; systemic, rectal
9.1
25.2
59
98
JN4AD
NOMESCO Finland
Body CT examination
20.7
24.7
37
23
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
23.5
22
*
A04AA01
ATC
ondansetron; systemic, rectal
23.9
21.9
31
16
L03AA13
ATC
pegfilgrastim; parenteral
+∞
21.3
20
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
21.3
20
*
NER30
NOMESCO Finland
Extended excision of soft tissue tumour of pelvis
+∞
21.3
20
*
C90.2
ICD-10 Finland
Extramedullary plasmacytoma
+∞
18.1
17
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
18.1
17
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
17.0
16
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
34.4
16.6
21
7
WW300
NOMESCO Finland
Transfer of autologic stem cells
+∞
15.9
15
*
WZC30
NOMESCO Finland
Teaching
7.5
15.8
39
66
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
17.5
15.5
24
16
N03AX16
ATC
pregabalin; oral
4.6
15.1
64
207
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.2
15.0
53
141
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
17.8
15.0
23
15
153
Kela drug reimbursment
Lenalidomid
+∞
14.8
14
*
9220/3-C41.3
ICD-O-3
Chondrosarcoma, NOS, of rib, sternum, clavicle and associated joints
+∞
14.8
14
*
C41.49
ICD-10 Finland
Malignant tumor of the pelvic bones, sacrum and coccyx other or unspecified histology
+∞
14.8
14
*
JN4CD
NOMESCO Finland
Very extensive body CT
22.7
14.2
20
10
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
13.7
13
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
13.7
13
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
13.7
13
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.7
13.5
98
491
WX408
NOMESCO Finland
General anesthesy, balanced
4.0
13.3
67
248
R4110
NOMESCO Finland
Physiotherapy
4.0
13.1
65
235
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
9.5
12.7
26
32
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
12.7
12
*
L04AX04
ATC
lenalidomide; oral
+∞
12.7
12
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
12.7
12
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
12.7
12
*
9370/3-C41.4
ICD-O-3
Chordoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
12.7
12
*
Z51.5
ICD-10 Finland
Palliative care
13.3
12.3
21
18
WW500
NOMESCO Finland
Blood transfusion
16.4
12.2
19
13
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
50.9
12.1
14
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.8
12.0
31
55
B01AB05
ATC
enoxaparin; parenteral
3.6
12.0
71
296
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
70.4
11.8
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.7
11.7
35
75
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
11.6
11
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
11.6
11
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
+∞
11.6
11
*
C41.42
ICD-10 Finland
Chondrosarcoma of the pelvic bones, sacrum and coccyx
+∞
11.6
11
*
GAE06
NOMESCO Finland
Excision of lesion of chest wall
+∞
11.6
11
*
C41.32
ICD-10 Finland
Chondrosarcoma of the ribs, sternum and clavicle
+∞
11.6
11
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
12.6
11.4
20
18
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
7.4
10.9
26
41
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
10.5
10
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
10.5
10
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
10.5
10
*
C41.40
ICD-10 Finland
Pelvic bones, sacrum and coccyx
+∞
10.5
10
*
329
Kela drug reimbursment
Lenalidomide
+∞
10.5
10
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
10.5
10
*
B01AB10
ATC
tinzaparin; parenteral
9.2
10.2
21
26
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
18.3
10.1
15
9
NE1AA
NOMESCO Finland
Pelvis X-ray examination
5.4
9.8
30
66
NE1DG
NOMESCO Finland
Pelvic, hip and femur very extensive MRI examination with high intensity magnet
58.8
9.8
11
*
ZX112
NOMESCO Finland
Subcutaneous
58.8
9.8
11
*
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
11.8
9.6
17
16
9731/3-C41.3
ICD-O-3
Plasmacytoma, NOS, of rib, sternum, clavicle and associated joints
+∞
9.5
9
*
9220/3-C41.4
ICD-O-3
Chondrosarcoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
9.5
9
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
9.5
9
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
9.5
9
*
WX402
NOMESCO Finland
General anaesthesia
3.9
9.1
41
132
ZX120
NOMESCO Finland
Intravenous
5.1
9.1
29
67
AA1AA
NOMESCO Finland
Head X-ray examination
25.8
9.1
12
5
TPX10
NOMESCO Finland
Implantation of vascular injection port
15.2
8.9
14
10
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.6
8.8
31
79
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
10.3
8.5
16
17
R50.9
ICD-10 Finland
Fever, unspecified
3.8
8.5
38
122
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
8.4
8
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
8.4
8
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
8.4
8
*
9731/3-C41.2
ICD-O-3
Plasmacytoma, NOS, of vertebral column
+∞
8.4
8
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
8.4
8
*
JN6AD
NOMESCO Finland
CT of torso and neck
35.4
8.2
10
*
GD1AD
NOMESCO Finland
Thorax CT examination
9.2
8.0
16
19
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.7
7.8
22
44
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.6
7.7
37
125
C41.22
ICD-10 Finland
Chondrosarcoma of the spine
+∞
7.3
7
*
C41.3
ICD-10 Finland
Malignant neoplasm: Ribs, sternum and clavicle
+∞
7.3
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.3
7
*
GAE23
NOMESCO Finland
Resection of chest wall and prosthetic repair
+∞
7.3
7
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
7.3
7
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
7.3
7
*
9680/3-C41.4
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
7.3
7
*
C41.41
ICD-10 Finland
Osteosarcoma of the pelvic bones, sacrum and coccyx
+∞
7.3
7
*
NER20
NOMESCO Finland
Incomplete excision of soft tissue tumour of pelvis
+∞
7.3
7
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
21.2
7.2
10
5
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
7.8
6.9
15
21
A02BC02
ATC
pantoprazole; systemic
2.5
6.9
107
727
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
41.9
6.8
8
*
J05AB01
ATC
aciclovir; systemic
2.8
6.5
46
202
NK6BN
NOMESCO Finland
Bone dynamic isotope examination
72.7
6.5
7
*
N02BE01
ATC
paracetamol; systemic, rectal
3.2
6.4
136
1074
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.8
6.3
20
46
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
27.9
6.3
8
*
NEA20
NOMESCO Finland
Exploration of soft tissue of pelvis,v
+∞
6.3
6
*
WW402
NOMESCO Finland
Leucoferesis
+∞
6.3
6
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
6.3
6
*
YNB10
NOMESCO Finland
Collection of stem cells for transplant
+∞
6.3
6
*
NK1AT
NOMESCO Finland
Muscle biopsy with ultrasound guidance
+∞
6.3
6
*
9220/3-C41.0
ICD-O-3
Chondrosarcoma, NOS, of bones of skull and face and associated joints
+∞
6.3
6
*
WW409
NOMESCO Finland
Other aferesis
+∞
6.3
6
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.3
6
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
A06AH03
ATC
naloxegol; oral
+∞
6.3
6
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
6.3
6
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
6.2
55
275
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
82
8.54
44.03
10.1
1.3
34.0
44.6
mg/l
1.00
50
67
61
83
8.43
43.58
10.0
1.3
40.4
30.5
mg/l
0.20
50
69
277
1568
3.27
29.30
12.5
4.2
11.1
12.0
umol/l
0.25
265
1476
248
1322
3.15
29.05
6.8
3.9
34.3
35.8
g/l
3.42
236
1227
72
171
4.88
29.02
4.8
1.6
48.6
4.5
ug/l
0.68
53
131
289
1723
3.19
27.03
19.9
6.4
4.2
4.3
e9/l
0.23
266
1507
264
1537
2.95
25.00
17.7
6.1
1.2
1.2
mmol/l
1.48
222
1325
246
1392
2.86
24.36
13.3
6.0
1.2
1.2
mmol/l
1.51
226
1244
240
1341
2.85
24.35
6.7
3.8
—
—
—
0
0
195
990
2.82
23.60
7.4
2.1
2.3
2.4
mmol/l
0.91
179
820
147
678
2.80
20.92
4.7
2.1
—
—
—
0
0
20
20
10.45
17.72
1.6
2.1
13.7
11.9
%
—
9
12
38
79
5.19
17.68
1.8
1.4
—
—
—
0
0
19
18
11.01
17.44
1.7
2.3
—
—
—
0
0
92
365
2.95
16.97
10.1
8.8
1.7
1.4
mmol/l
0.30
72
286
330
2438
2.68
15.48
15.7
5.3
89.4
76.1
u/l
3.12
319
2244
277
1893
2.37
15.41
8.7
4.7
6.6
6.7
mmol/l
0.91
269
1766
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
38
91
4.49
14.93
2.4
3.9
0.4
0.3
u/ml
0.05
21
50
29
62
4.95
13.03
1.8
1.6
—
—
—
0
0
21
33
6.65
12.94
3.3
1.5
—
—
—
0
0
105
511
2.41
12.55
2.3
1.8
—
—
—
0
0
181
1118
2.09
11.94
4.1
3.2
—
—
—
0
0
111
565
2.31
11.92
4.7
2.1
2.5
2.4
mmol/l
0.66
100
480
36
99
3.88
11.77
6.5
1.3
2.3
0.6
g/l
0.50
28
86
40
119
3.61
11.69
7.2
1.3
—
—
—
0
0
40
119
3.61
11.69
7.2
1.3
3.6
3.7
g/l
0.22
22
82
40
119
3.61
11.69
7.1
1.3
7.5
7.4
g/l
0.05
26
87
16
21
7.88
11.49
1.1
1.3
13.7
15.9
ug/l
0.31
16
21
70
293
2.67
11.42
4.6
2.8
—
—
—
0
0
37
108
3.66
11.12
2.0
1.8
2.3
1.8
ug/l
0.10
31
98
100
504
2.29
10.90
3.4
2.0
29.2
29.7
s
0.44
95
485
27
66
4.30
10.32
1.9
1.5
—
—
—
0
0
19
34
5.81
10.31
1.2
1.1
—
—
—
0
0
28
71
4.16
10.21
1.9
1.7
10.3
7.5
u/l
0.49
21
62
23
50
4.81
10.13
1.9
1.5
—
—
—
0
0
27
67
4.24
10.12
1.8
1.4
—
—
—
0
0
142
852
2.01
9.73
4.3
2.4
6273.5
9729.5
umol/l
0.40
133
736
19
36
5.48
9.72
1.5
1.4
—
—
—
0
0
35
111
3.35
9.28
7.6
1.4
3.1
3.0
g/l
0.26
22
83
12
5
24.64
8.95
10.9
1.0
30.8
16.2
u/ml
—
12
5
140
862
1.94
8.75
3.5
3.0
0.9
0.4
e6/l
0.39
104
631
33
107
3.26
8.45
8.8
1.3
8.9
10.8
g/l
2.03
26
90
13
20
6.68
8.11
1.7
1.6
485.8
541.3
e6/l
—
8
14
16
31
5.33
7.99
1.6
1.6
—
—
—
0
0
50
212
2.54
7.88
3.6
4.9
2.1
2.2
mmol/l
0.04
45
151
20
50
4.15
7.43
1.3
1.4
—
—
—
0
0
10
5
20.43
7.16
1.8
3.4
—
—
—
0
0
47
203
2.48
7.12
2.1
1.4
—
—
—
0
0
70
360
2.13
7.07
3.4
2.7
5.1
6.8
umol/l
1.39
63
312
46
201
2.45
6.80
2.0
1.5
—
—
—
0
0
70
367
2.09
6.72
2.1
1.8
—
—
—
0
0
261
2051
1.73
6.61
5.7
4.3
11.2
1069.3
e6/l
—
5
37
19
50
3.93
6.61
5.4
3.4
63.3
59.1
%
0.63
19
50
70
371
2.07
6.52
2.1
1.7
—
—
—
0
0
15
34
4.54
6.28
3.3
1.9
31.8
33.7
pg
0.92
15
34
27
93
3.03
6.28
2.6
5.5
8.3
8.7
kpa
0.57
27
84
18
49
3.79
5.98
4.7
3.0
4.3
4.4
e9/l
0.08
18
49
14
32
4.49
5.81
1.4
1.5
—
—
—
0
0
83
488
1.87
5.71
3.3
2.4
12.2
13.9
umol/l
1.14
77
444
52
259
2.15
5.68
2.6
2.1
68.8
67.0
ml/min/173m2
0.11
28
102
11
21
5.35
5.55
2.4
2.5
—
—
—
0
0
123
820
1.71
5.53
5.0
3.8
0.0
0.0
estimate
0.00
44
245
69
401
1.86
4.89
3.2
2.5
22.0
23.7
%
0.40
60
346
119
809
1.66
4.89
2.3
2.2
3.2
3.0
mg/l
0.28
101
684
13
33
4.03
4.74
4.4
1.8
3.7
126.5
u/ml
0.55
13
33
25
98
2.65
4.64
2.7
3.5
—
—
—
0
0
24
94
2.65
4.47
7.2
1.2
39.4
38.7
g/l
0.31
19
76
38
185
2.16
4.41
2.1
1.6
—
—
—
0
0
52
285
1.94
4.40
16.2
7.4
1.2
1.4
mmol/l
1.71
52
274
26
109
2.48
4.23
2.3
1.6
—
—
—
0
0
174
1331
1.53
4.22
4.3
3.7
28.1
40.2
ng/l
1.32
140
965
7
7
10.14
4.02
1.4
1.0
—
—
—
0
0
7
7
10.14
4.02
1.4
1.0
—
—
—
0
0
286
2447
1.53
3.96
5.6
4.0
17.4
11.6
mm/h
4.94
274
2242
13
38
3.50
3.93
1.7
1.4
—
—
—
0
0
27
120
2.34
3.89
2.8
1.6
—
—
—
0
0
139
1031
1.52
3.81
3.8
3.2
1097.1
1550.8
ng/l
1.18
126
880
12
34
3.60
3.79
1.8
1.5
—
—
—
0
0
7
8
8.87
3.78
1.0
5.0
85.4
84.4
%
—
7
8
51
293
1.84
3.75
5.5
3.4
4.3
4.6
kpa
0.67
51
282
138
1028
1.51
3.69
2.3
2.2
52.6
56.7
u/l
0.73
133
949
13
40
3.32
3.65
1.2
1.1
—
—
—
0
0
57
342
1.77
3.64
7.8
3.8
6.0
5.8
kpa
0.69
57
331
16
57
2.88
3.56
1.4
1.3
—
—
—
0
0
309
2715
1.53
3.55
33.8
14.9
14.2
13.6
%
9.12
301
2662
13
41
3.24
3.52
1.5
1.4
—
—
—
0
0
6
6
10.12
3.50
1.5
1.0
—
—
—
0
0
6
6
10.12
3.50
1.5
1.0
—
—
—
0
0
159
1231
1.47
3.48
5.2
3.8
—
—
—
0
0
358
3262
1.68
3.43
31.3
12.4
28.2
23.5
mg/l
2.21
329
2524
10
28
3.63
3.21
3.3
2.1
—
—
—
0
0
26
125
2.15
3.15
2.5
1.7
1.2
1.4
g/l
0.90
19
108
163
1288
1.44
3.13
2.4
2.4
78.6
77.6
nmol/l
0.17
153
1143
97
692
1.52
3.12
3.0
1.8
2.3
1.2
mg/l
0.51
79
531
55
342
1.70
3.11
8.0
3.8
2.5
2.0
mmol/l
0.48
47
268
10
29
3.51
3.06
1.1
1.0
—
—
—
0
0
66
435
1.61
2.99
7.1
7.4
—
—
—
0
0
192
1573
1.41
2.98
4.8
3.7
0.0
0.0
estimate
0.00
45
253
13
46
2.88
2.94
1.5
1.3
—
—
—
0
0
335
3040
1.51
2.88
27.6
11.2
81.0
79.5
ml/min/173m2
0.56
297
2436
6
9
6.74
2.87
4.2
1.2
66.5
73.9
nmol/l
—
6
9
18
77
2.40
2.86
1.5
1.6
—
—
—
0
0
190
1568
1.39
2.76
6.4
5.2
0.0
0.0
estimate
0.00
45
252
8
19
4.27
2.69
5.1
1.4
—
—
—
0
0
17
73
2.39
2.68
1.6
1.4
—
—
—
0
0
17
73
2.39
2.68
1.6
1.4
—
—
—
0
0
74
515
1.53
2.66
3.8
2.8
2.8
2.1
e6/l
0.26
41
282
7
15
4.73
2.60
1.3
1.6
—
—
—
0
0
9
25
3.66
2.59
1.3
1.2
—
—
—
0
0
5
7
7.21
2.55
1.0
2.0
—
—
—
0
0
307
3332
0.70
2.49
4.6
5.2
2.7
2.7
mmol/l
0.49
272
3062
8
21
3.86
2.47
1.6
1.6
—
—
—
0
0
12
45
2.72
2.47
1.4
1.3
—
—
—
0
0
77
553
1.48
2.38
3.0
2.6
0.9
1.1
e6/l
0.26
42
318
189
1589
1.35
2.33
4.9
3.7
0.0
0.0
estimate
0.00
45
243
12
47
2.60
2.29
2.1
1.3
142.8
60.0
pmol/l
0.64
12
47
5
9
5.61
2.22
10.4
3.0
—
—
—
0
0
161
1337
1.33
2.11
3.3
2.7
408.6
125.2
ug/l
1.17
148
1232
30
177
1.75
2.08
4.4
2.7
0.3
0.2
e6/l
0.27
30
170
300
3243
0.73
2.07
4.2
4.6
1.4
1.4
mmol/l
1.40
269
2972
5
10
5.05
2.07
2.6
1.4
—
—
—
0
0
5
10
5.05
2.07
2.6
1.4
—
—
—
0
0
5
10
5.05
2.07
2.0
1.8
—
—
—
0
0
5
10
5.05
2.07
2.6
1.4
—
—
—
0
0
5
10
5.05
2.07
2.0
1.8
—
—
—
0
0
6
15
4.04
2.04
1.8
1.3
—
—
—
0
0
6
15
4.04
2.04
1.0
1.0
—
—
—
0
0
303
3268
0.74
2.03
4.3
4.6
4.5
4.6
mmol/l
0.55
274
3013
6
17
3.56
1.84
1.8
1.5
—
—
—
0
0
17
87
1.99
1.82
1.6
1.1
—
—
—
0
0
7
24
2.95
1.73
1.6
1.2
2.3
1.8
mmol/l
—
7
24
5
13
3.88
1.72
2.6
1.4
—
—
—
0
0
5
13
3.88
1.72
1.6
2.2
—
—
—
0
0
5
13
3.88
1.72
2.6
1.4
—
—
—
0
0
5
13
3.88
1.72
2.6
1.4
—
—
—
0
0
5
13
3.88
1.72
2.6
1.4
—
—
—
0
0
8
31
2.61
1.66
1.0
1.0
—
—
—
0
0
8
31
2.61
1.66
2.1
1.1
—
—
—
0
0
37
247
1.55
1.64
2.7
2.3
10.6
15.5
nmol/l
3.51
30
222
102
821
1.32
1.61
1.7
1.5
20.1
21.1
nmol/l
0.27
92
696
8
32
2.53
1.60
2.1
1.1
—
—
—
0
0
8
32
2.53
1.60
2.1
1.1
—
—
—
0
0
361
3421
1.41
1.60
35.0
15.2
139.1
139.7
mmol/l
4.05
355
3322
7
26
2.72
1.58
2.4
1.3
—
—
—
0
0
7
26
2.72
1.58
2.4
1.3
—
—
—
0
0
7
26
2.72
1.58
2.4
1.3
—
—
—
0
0
81
633
1.35
1.57
1.8
1.8
1359.1
1205.1
nmol/l
0.47
63
469
8
33
2.45
1.54
2.1
1.1
—
—
—
0
0
8
33
2.45
1.54
2.1
1.1
—
—
—
0
0
8
33
2.45
1.54
2.1
1.1
—
—
—
0
0
291
3119
0.78
1.52
3.9
4.2
1.3
1.3
mmol/l
0.16
265
2843
287
3080
0.78
1.51
5.9
6.1
39.9
40.2
mmol/mol
0.25
265
2855
361
3430
1.38
1.49
35.2
15.3
4.0
4.0
mmol/l
0.51
355
3323
16
275
0.57
1.44
1.4
2.0
—
—
—
0
0
87
696
1.32
1.44
1.7
1.7
473.4
12875204.1
pmol/l
0.50
72
567
126
1064
1.26
1.37
2.2
2.1
182.3
319.4
u/l
0.97
120
998
5
17
2.96
1.36
1.0
1.1
—
—
—
0
0
14
76
1.87
1.31
1.3
1.2
3.7
4.0
mmol/l
0.43
14
71
44
591
0.71
1.31
1.4
1.3
59.1
35.4
iu/ml
0.24
15
192
33
233
1.45
1.17
6.5
2.9
119.9
130.4
g/l
2.37
33
228
74
906
0.78
1.17
1.7
1.7
1.4
1.4
mmol/l
0.34
64
755
157
1381
1.22
1.16
2.0
2.0
89.7
94.9
pmol/l
0.68
96
703
20
305
0.64
1.15
1.5
2.1
—
—
—
0
0
0
36
0.00
1.14
0.0
1.5
—
—
—
0
0
5
21
2.40
1.09
1.0
1.6
—
—
—
0
0
17
105
1.65
1.07
1.3
1.1
—
—
—
0
0
17
264
0.63
1.07
1.7
1.8
—
—
—
0
0
265
2464
1.21
1.06
4.6
3.6
14.8
14.9
pmol/l
0.24
237
2224
17
106
1.63
1.04
1.3
1.1
—
—
—
0
0
364
3503
1.30
1.03
19.5
8.8
25.9
26.0
u/l
0.02
354
3354
14
84
1.69
0.99
1.3
1.5
14552.5
17425.4
e6/l
—
8
65
7
37
1.91
0.94
1.4
1.4
—
—
—
0
0
7
37
1.91
0.94
1.4
1.4
—
—
—
0
0
43
544
0.77
0.89
1.2
1.3
29.9
12.7
u/ml
0.38
14
208
13
79
1.67
0.89
1.6
1.7
262.6
256.1
mu/l
0.05
13
73
14
87
1.63
0.88
1.6
1.3
460.0
468.7
mg/l
0.04
14
81
6
30
2.01
0.87
6.2
4.6
—
—
—
0
0
37
283
1.34
0.87
2.3
1.9
45.4
29.7
u/l
0.66
26
234
89
762
1.21
0.85
5.0
3.9
1.0
1.0
kg/l
0.01
15
123
6
33
1.83
0.79
1.3
1.2
—
—
—
0
0
0
27
0.00
0.77
0.0
1.4
—
—
—
0
0
0
28
0.00
0.76
0.0
1.5
—
—
—
0
0
0
28
0.00
0.76
0.0
1.2
—
68.0
—
0
5
7
39
1.81
0.73
1.0
1.0
—
—
—
0
0
7
41
1.72
0.70
1.7
1.8
—
—
—
0
0
18
246
0.72
0.65
2.7
2.5
—
20.0
—
0
10
310
3215
0.86
0.64
4.6
4.7
6.0
6.0
mmol/l
0.19
280
2911
54
455
1.21
0.62
18.2
27.5
1.6
1.3
inr
—
7
65
10
63
1.60
0.62
1.9
1.1
—
—
—
0
0
5
30
1.67
0.61
1.4
1.4
—
—
—
0
0
26
201
1.31
0.60
1.3
1.2
655.3
247.6
u/ml
0.36
26
183
8
52
1.55
0.59
1.1
1.2
—
—
—
0
0
17
123
1.40
0.59
1.4
2.2
—
—
—
0
0
8
53
1.52
0.58
1.3
1.4
—
—
—
0
0
225
2126
1.13
0.57
3.1
3.0
55.1
46.0
u/l
0.85
212
1977
9
134
0.66
0.52
1.4
2.2
—
—
—
0
0
206
1948
1.11
0.50
2.6
2.9
—
—
—
0
0
7
106
0.65
0.49
1.3
2.1
—
—
—
0
0
23
181
1.29
0.49
6.4
2.8
1.1
1.1
%
0.02
23
181
23
181
1.29
0.49
8.1
3.0
25.6
25.0
mmol/l
0.30
23
176
309
2990
1.13
0.48
28.9
13.7
36.9
40.2
%
6.65
205
2072
15
112
1.35
0.45
2.2
2.1
487.5
738.5
ug/l
0.23
15
104
7
50
1.41
0.45
1.0
1.3
—
—
—
0
0
134
1245
1.11
0.44
4.3
3.8
6.5
2.0
ug/l
0.67
119
1102
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
9
70
1.29
0.37
1.3
1.3
—
—
—
0
0
5
79
0.63
0.36
1.4
1.4
—
—
—
0
0
6
43
1.40
0.35
1.2
1.0
—
—
—
0
0
20
166
1.22
0.30
1.3
1.3
—
—
—
0
0
11
84
1.32
0.30
1.2
1.3
—
—
—
0
0
8
62
1.30
0.28
2.1
1.5
—
—
—
0
0
9
77
1.17
0.24
1.1
1.1
—
—
—
0
0
371
3665
1.11
0.24
44.4
18.2
4.3
4.5
e12/l
15.17
359
3546
5
38
1.32
0.23
1.2
1.1
—
—
—
0
0
5
38
1.32
0.23
1.2
1.1
—
—
—
0
0
13
157
0.82
0.23
1.0
1.0
—
—
—
0
0
307
3015
1.07
0.22
5.3
4.4
1.9
1.9
mu/l
0.05
278
2732
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
46
422
1.10
0.21
4.1
4.7
30.7
32.4
%
0.58
32
269
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
32
289
1.12
0.19
2.0
3.3
122.8
197.5
ng/l
1.25
27
263
6
52
1.16
0.19
1.2
1.5
—
0.7
nmol/l
—
0
7
96
998
0.95
0.14
4.5
3.7
22.6
24.0
%
0.36
44
467
11
95
1.16
0.11
1.4
1.3
—
—
—
0
0
67
694
0.96
0.09
2.6
2.6
0.8
0.7
ug/l
0.29
44
461
51
530
0.96
0.08
1.2
1.5
—
—
—
0
0
9
85
1.06
0.07
1.3
1.1
—
—
—
0
0
71
691
1.03
0.06
3.7
3.9
87.3
422.5
ng/l
2.05
54
541
10
92
1.09
0.03
1.2
1.7
—
—
—
0
0
11
103
1.07
0.02
1.5
1.6
—
—
—
0
0
35
358
0.98
0.01
1.8
1.9
1.6
1.5
%
0.11
30
310
37
378
0.98
0.01
1.7
1.4
—
—
—
0
0
71
702
1.01
0.01
1.2
1.3
1.6
2.5
u/ml
0.44
20
187
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
1.3
—
0
8
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_BONE_CARTILAGE_NAS_EXALLC – Malignant neoplasm of bone and articular cartilage of other and unspecified sites, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).